Go Deep
Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -16,820 | -0.0 | -0.03 | -0.80 | 40.70 |
| Oct 2026 | -16,765 | -0.0 | -0.02 | -0.80 | 29.91 |
| Oct 2026 | -16,782 | -0.0 | -0.02 | -0.80 | 33.31 |
| Oct 2026 | -16,802 | -0.0 | -0.03 | -0.80 | 36.95 |
| Oct 2026 | -17,480 | -0.0 | -0.02 | -0.80 | 32.81 |
| Oct 2026 | -17,487 | -0.0 | -0.03 | -0.80 | 34.00 |
| Oct 2026 | -17,519 | -0.0 | -0.03 | -0.80 | 40.14 |
| Oct 2026 | -17,579 | -0.0 | -0.04 | -0.80 | 51.55 |
Karyopharm Therapeutics Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 33,432,000.0 | 35,066,000.0 | 34,079,000.0 | 44,044,000.0 |
| Net Profit | -67,023,000.0 | -22,392,000.0 | -102,198,000.0 | -33,127,000.0 |
| EPS | -2.3 | -1.0 | -5.7 | -3.8 |
Karyopharm Therapeutics Inc. Revenue & Profit: Last 5 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Revenue | 146,067,000.0 | 145,237,000.0 | 146,033,000.0 | 157,074,000.0 | — |
| Net Profit | -196,039,000.0 | -76,422,000.0 | -143,099,000.0 | -165,291,000.0 | — |
| EPS | -17.9 | -9.4 | -18.8 | -30.3 | — |
Karyopharm Therapeutics Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Total Assets | 108,416,000.0 | 164,418,000.0 | 240,438,000.0 | 358,172,000.0 | — |
| Total Liabilities | 401,342,000.0 | 350,435,000.0 | 376,644,000.0 | 374,828,000.0 | — |
| Total Equity | -292,926,000.0 | -186,017,000.0 | -136,206,000.0 | -16,656,000.0 | — |
Owes vs Owns
Karyopharm Therapeutics Inc. owed $3.97 for every $1 it owned in Jun 2026, up from $1.05 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 3.97× | 3.70× | 2.13× | 1.57× | 1.05× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Karyopharm Therapeutics Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 58.8%Receivables 24.1%Inventory 3.7%Fixed assets (tangible) 4.3%Other assets 9.0%
How it's funded — Dec 2025
Short-term debt 5.2%Long-term debt 51.3%Payables 1.0%Other liabilities 42.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 63.7 | 108.7 | 191.4 | 278.0 |
| Receivables | 26.2 | 30.8 | 27.0 | 47.1 |
| Inventory | 4.0 | 4.7 | 3.0 | 4.2 |
| Fixed assets (tangible) | 4.7 | 6.3 | 4.9 | 7.4 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 9.8 | 13.9 | 14.1 | 21.5 |
| Liabilities & equity | ||||
| Short-term debt | 21.0 | 24.4 | 3.3 | 2.9 |
| Long-term debt | 205.9 | 162.9 | 170.9 | 170.1 |
| Payables | 4.0 | 5.1 | 3.1 | 2.8 |
| Other liabilities | 170.4 | 158.0 | 199.3 | 199.1 |
| Shareholders' equity | -292.9 | -186.0 | -136.2 | -16.7 |
| Net tangible assets | -292.9 | -186.0 | -136.2 | -16.7 |
Karyopharm Therapeutics Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Operating Activities | -75,369,000.0 | -127,486,000.0 | -92,723,000.0 | -149,554,000.0 | — |
| Investing Activities | 43,378,000.0 | 95,473,000.0 | 7,940,000.0 | -104,256,000.0 | — |
| Financing Activities | 30,048,000.0 | 41,646,000.0 | 1,124,000.0 | 193,738,000.0 | — |